Navigation Links
Breaking Study: ICU Medical's Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
Date:12/13/2011

SAN CLEMENTE, Calif., Dec. 13, 2011 /PRNewswire/ --  ICU Medical, Inc. (NASDAQ: ICUI) announced that a clinical study presented at the American Society of Nephrology's (ASN) Kidney Week 2011 showed the Tego® needlefree hemodialysis connector can decrease heparin use and reduce costs for dialysis clinics. As the world's first and only needlefree connector FDA-cleared for use in hemodialysis applications, the Tego connector provides a cost effective alternative to traditional connectors without affecting blood flow rate or the rate of positive blood cultures.

For the study titled Tego® Connectors Reduce Heparin Use without Affecting Blood Flow Rate Compared to Traditional Central Venous Catheter Locks, researchers from DaVita Clinical Researchä (DCR), a provider of clinical research services focused on kidney research as well as a multitude of specialty therapeutic populations, analyzed clinical data from more than 2,500 patients, comparing conversion from traditional central venous catheter (CVC) locks to Tego connectors. Researchers examined data gathered 90 days before and 90 days immediately following the Tego conversion, evaluating blood flow rate, heparin use, and blood culture results. From this data, a cost analysis was conducted, comparing the cost of heparin, connectors, syringes, activase, sodium citrate, and equipment for both CVC locks and Tego connectors to the cost of recombinant tissue plasminogen activator (rt-PA).

Researchers showed that total heparin use decreased by nearly 2000 units three months after the Tego conversion, reducing costs by an average of $16.38 per CVC compared to traditional CVC locks, and "significantly" reducing costs when compared to rt-PA. This study provides evidence to support the Tego's ability to reduce costs associated with long-term CVC without the use of heparin CVC locks. The researchers concluded that since blood flow rate and the rate of positive blood cultures were essentially unchanged after conversion that "Tego connectors are a viable and cost-effective alternative to traditional locks."

Media Contact: Tom McCall 
Vice President, Marketing
949-366-4368
tmccall@icumed.com

About ICU Medical, Inc.: ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. ICU Medical's products improve patient outcomes by helping prevent bloodstream infections and protecting healthcare workers from exposure to infectious diseases or hazardous drugs. The company's complete product line includes custom I.V. systems, closed delivery systems for hazardous drugs, needlefree I.V. connectors, catheters and cardiac monitoring systems. ICU Medical is headquartered in San Clemente, California.

 


'/>"/>
SOURCE ICU Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
2. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
3. Data From REMEDEE Trial Featuring OrbusNeichs Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011
4. Campaign for Cancer Prevention Connects 6 Million+ Members on Facebook Causes to Groundbreaking Research at Brigham and Womens Hospital
5. Breaking Kashas rule
6. ERA-EDTA Congress 2011: Late Breaking Clinical Trials I
7. Breaking the ice before it begins
8. Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility
9. BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient
10. Groundbreaking International Training Lab to Strengthen Food Safety in U.S. and Globally
11. Texas-Based Consortium Announces Project GreenVax: A Groundbreaking Vaccine Manufacturing Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® ... Farming in 2017 and Beyond. The paper outlines the key trends that are ... industry. , “We’ve witnessed a lot of highs and lows as the precision ...
(Date:5/23/2016)... CA (PRWEB) , ... May 23, 2016 , ... ... public interest organization focused on molecular nanotechnology, announced the winners for the 2015 ... pioneer physicist Richard Feynman, are given in two categories, one for experiment and ...
(Date:5/20/2016)... Baltimore, MD (PRWEB) , ... May 20, 2016 , ... ... contaminated with Listeria, as reported by Food Safety News on May 12, 2016(1), demonstrates ... according to Ted Olsen, CEO of Baltimore-based biotech firm, PathSensors, Inc. ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
Breaking Biology Technology:
(Date:3/14/2016)... http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ( ... --> DERMALOG, le leader de l,innovation ... d,empreintes digitales pour l,enregistrement des réfugiés en Allemagne. ... produire des cartes d,identité aux réfugiés. DERMALOG dévoilera ...
(Date:3/10/2016)... March 10, 2016   Unisys Corporation (NYSE: ... Protection (CBP) is testing its biometric identity solution at ... to help identify certain non-U.S. citizens leaving the ... test, designed to help determine the efficiency and accuracy of ... February and will run until May 2016. --> ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
Breaking Biology News(10 mins):